托珠单抗与利妥昔单抗在类风湿关节炎相关间质性肺病中的比较有效性:一项模拟目标试验
本研究利用TriNetX美国协作网络数据库,模拟目标试验比较托珠单抗与利妥昔单抗治疗类风湿关节炎相关间质性肺病(RA-ILD)的预后。经倾向评分匹配后每组各1194例患者,5年全因死亡率无显著差异(HR 1.073,95%CI 0.881-1.305),住院和机械通气风险也相当。但在基线炎症标志物升高的患者中,托珠单抗组机械通气(HR 1.936,95%CI 1.125-3.331)和全因死亡(HR 1.403,95%CI 1.013-1.942)风险更高。作者认为,在基线炎症标志物升高的RA-ILD患者中,利妥昔单抗可能是比托珠单抗更安全的选择。
要点
- 在RA-ILD患者中,托珠单抗与利妥昔单抗的5年全因死亡率无显著差异(HR 1.073,95%CI 0.881-1.305)。
- 两组住院和机械通气风险也相当。
- 基线炎症标志物升高的RA-ILD患者使用托珠单抗,机械通气风险更高(HR 1.936,95%CI 1.125-3.331)。
- 基线炎症标志物升高的RA-ILD患者使用托珠单抗,全因死亡风险更高(HR 1.403,95%CI 1.013-1.942)。
- 未使用过TNF抑制剂且炎症标志物升高的患者,托珠单抗组机械通气风险增加(HR 1.539,95%CI 1.074-2.206)。
适用人群与场景
- 类风湿关节炎相关间质性肺病(RA-ILD)患者。
- 排除其他系统性自身免疫性风湿病相关间质性肺病的患者后,结果一致。
研究设计与关键结果
- 研究类型:模拟目标试验的回顾性队列研究,使用TriNetX美国协作网络数据库。
- 样本量:倾向评分匹配后每组各1194例患者。
- 主要终点:5年全因死亡率,托珠单抗组与利妥昔单抗组无显著差异(HR 1.073,95%CI 0.881-1.305)。
- 次要终点:住院和机械通气风险两组相当。
- 敏感性分析:基线炎症标志物升高的患者中,托珠单抗组机械通气风险更高(HR 1.936,95%CI 1.125-3.331),全因死亡风险更高(HR 1.403,95%CI 1.013-1.942)。
- 亚组分析:未使用过TNF抑制剂且炎症标志物升高的患者,托珠单抗组机械通气风险增加(HR 1.539,95%CI 1.074-2.206)。
证据类型、等级与局限
- 证据类型:回顾性队列研究(模拟目标试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在RA-ILD患者中,托珠单抗与利妥昔单抗的5年全因死亡率和医疗使用风险无显著差异。
- 作者认为,在基线炎症标志物升高的RA-ILD患者中,利妥昔单抗可能是比托珠单抗更安全的选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) confers an increased risk of mortality among patients with RA. However, the optimal treatment strategies remain uncertain due to the limited high-quality evidence available.
RESEARCH QUESTION: In patients with RA-ILD, how does tocilizumab compare with rituximab in terms of prognosis?
STUDY DESIGN AND METHODS: This study used the TriNetX US Collaborative Network database to emulate a target trial of patients with RA-ILD treated with either tocilizumab or rituximab. Propensity score matching was used to balance disease severity between groups. Primary and secondary outcomes included all-cause mortality and medical utilizations risk. Hazard ratios (HRs) were estimated by using Cox regression. Subgroup and sensitivity analyses were performed.
RESULTS: Each matched cohort included 1,194 patients. Over 5 years, all-cause mortality did not differ significantly between the tocilizumab and rituximab groups (HR, 1.073; 95% CI: 0.881-1.305). Secondary outcomes, including hospitalization and mechanical ventilation, were also comparable. Excluding patients with other systemic autoimmune rheumatic disease-related interstitial lung diseases yielded consistent results. In sensitivity analysis, patients with RA-ILD with elevated baseline inflammatory markers experienced higher risks with tocilizumab in mechanical ventilation (HR, 1.936; 95% CI, 1.125-3.331) and all-cause mortality (HR, 1.403; 95% CI: 1.013-1.942). In addition, patients naive to tumor necrosis factor inhibitor therapy with high inflammatory markers had an increased risk of mechanical ventilation (HR, 1.539; 95% CI, 1.074-2.206).
INTERPRETATION: In this real-world cohort, tocilizumab and rituximab displayed comparable effectiveness and safety in RA-ILD. However, among patients with elevated baseline inflammatory markers, rituximab might be a safer choice than tocilizumab.
参考来源
- Wu Z, Shih PC, Wang SI, et al. Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial. Chest. 2025. PMID: 40975268. doi:10.1016/j.chest.2025.09.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。